ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deeb, G. M.
Right arrow Articles by Nicklas, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deeb, G. M.
Right arrow Articles by Nicklas, J. M.

The Annals of Thoracic Surgery, Vol 48, 665-669, Copyright © 1989 by The Society of Thoracic Surgeons


ARTICLES

Amrinone versus conventional therapy in pulmonary hypertensive patients awaiting cardiac transplantation

GM Deeb, SF Bolling, TP Guynn and JM Nicklas
University of Michigan Medical Center, Ann Arbor.

Pulmonary hypertension is associated with an increased perioperative mortality for orthotopic heart transplantation. A transpulmonary gradient greater than 15 mm Hg or a pulmonary vascular resistance greater than 5 Woods units increases mortality secondary to right heart failure. This study compares amrinone with conventional therapy in 38 transplant candidates with pulmonary hypertension. All patients had elevated transpulmonary gradient, pulmonary vascular resistance, or both. Group 1 (n = 21) received prolonged continuous intravenous amrinone therapy, whereas group 2 (n = 16) received high-dose oral diuretics, digitalis, and captopril. Both groups 1 and 2 had decreased pulmonary hypertension, transpulmonary gradient, and pulmonary vascular resistance. However, amrinone was more effective, with a 86% response rate versus 63% response for conventional therapy. Survival awaiting transplantation was significantly higher in group 1 (20 of 22, 91%) than in group 2 (10 of 16, 63%). Although both groups 1 and 2 had significantly decreased pulmonary vascular resistance, only group 2 had significantly decreased systemic vascular resistance. Comparison of pulmonary vascular resistance after therapy showed that the response in group 1 (amrinone) was significantly lower than the response in group 2 (conventional therapy), suggesting that amrinone may function as a direct vasodilator of the pulmonary vasculature. There were no operative deaths or episodes of perioperative right heart failure in either group. Amrinone appears to be more effective and safe than conventional therapy in the treatment of prospective heart transplant candidates with pulmonary hypertension.


This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Murtra
The adventure of cardiac surgery
Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 167 - 180.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. A. Fullerton, S. D. Jones, J. Jaggers, F. Piedalue, RRT, F. L. Grover, and R. C. McIntyre Jr.
EFFECTIVE CONTROL OF PULMONARY VASCULAR RESISTANCE WITH INHALED NITRIC OXIDE AFTER CARDIAC OPERATION
J. Thorac. Cardiovasc. Surg., April 1, 1996; 111(4): 753 - 763.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1989 by The Society of Thoracic Surgeons.